In a clinical trial, DCs transduced with CCL21 using an adenoviral vector (Ad-CCL21-DC) were administrated to patients with lung cancer who had low infiltration of CD8+ T cells and were resistant to PD-1 therapy to attract T cells and DCs. This evidence concerns the gene CCL21 and lung carcinoma.